title: [How can we diagnose and better understand inflammatory myopathies? The usefulness of auto-antibodies].
abstract: The inflammatory myopathies are a group of quite proteiform, systemic auto-immune diseases which include polymyositis, dermatomyositis and inclusion body myopathies. To facilitate the diagnosis, classification criteria (Bohan and Peter, 1975) have been proposed, based essentially on clinical criteria. In addition, over the past fifteen years, auto-antibodies characterizing certain forms of inflammatory myopathy have been identified. One distinguishes schematically: auto-antibodies specific for myositis and auto-antibodies sometimes associated with myositis. Concerning the myositis specific auto-antibodies (MSA), schematically there are a dozen specificities which are classed according to the cellular distribution of the auto-antigen. The most characteristic are certainly the auto-antibodies directed against cytoplasmic antigens: the anti-tRNA synthetases (anti-Jo-1 (PL-1), anti-PL-7, PL-12, EJ, OJ, JS, KS, ZO, YRS), anti-SRP (signal recognition particle), anti-Mas and anti-KJ, anti-Fer (eEF1), anti-Wa and anti-CADM p140. Other auto-antibodies are directed against nuclear auto-antigens: the anti-Mi-2, anti-PMS (PMS1, PMS2) and related antibodies (MLH1, DNA PKcs…), anti-56 kDa, anti-MJ (NXP-2), anti-SAE and anti-p155/p140 (TIF-1γ). Concerning the auto-antibodies sometimes associated with myositis (myositis associated auto-antibodies or MAA), they can also be observed in other auto-immune diseases. These auto-antibodies are directed against nuclear or nucleolar auto-antigens: the anti-PM-Scl, anti-Ku, anti-RNP (U1 RNP and U2 RNP, U4/U6 RNP and U5 RNP), anti-Ro 52 kDa and more rarely, anti-Ro 60 kDa and anti-La. The auto-antibodies related to myositis are biological tools which are of interest in two main ways. They have allowed us to sort out the nosology of these inflammatory myopathies, in particular by defining anti-tRNA synthetase syndrome. It now remains to determine how they might be employed to complement the classical clinico-biological diagnostic criteria. In this perspective, it will be indispensable first of all to diffuse and standardize the methods of detection. The latter are at the moment very heterogeneous as they use techniques and above all antigenic preparations which are extremely diverse. These antibodies are also very interesting "physiopathological" tools to try to better understand myositis. The example of anti-tRNA synthetases is a particularly original model of auto-immunization, which allows one to establish a link between an initial, probably poorly specific muscular lesion and the appearance of auto-antibodies which maintain and aggravate the muscular disease.
authors.affiliation: CHU de Strasbourg, hôpital Hautepierre, service de rhumatologie, laboratoire d'immunologie, 67098 Strasbourg cedex, France. jean.sibilia@wanadoo.fr
authors.forename: Jean
authors.initials: J
authors.lastname: Sibilia
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Chatelus
authors.forename: Alain
authors.initials: A
authors.lastname: Meyer
authors.forename: Jacques-Eric
authors.initials: JE
authors.lastname: Gottenberg
authors.forename: Christelle
authors.initials: C
authors.lastname: Sordet
authors.forename: Joëlle
authors.initials: J
authors.lastname: Goetz
mesh_terms: D000604:Amino Acyl-tRNA Synthetases / Q000276:immunology; D000818:Animals; D001323:Autoantibodies / Q000276:immunology; D001324:Autoantigens / Q000276:immunology; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005095:Exoribonucleases; D063326:Exosome Multienzyme Ribonuclease Complex; D019084:Fluorescent Antibody Technique, Indirect; D006643:Histidine-tRNA Ligase / Q000276:immunology; D006801:Humans; D015151:Immunoblotting; D005779:Immunodiffusion; D007155:Immunologic Factors / Q000276:immunology; D056245:Mi-2 Nucleosome Remodeling and Deacetylase Complex / Q000276:immunology; D009220:Myositis / Q000145:classification / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology*; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins / Q000276:immunology; D043562:Receptors, G-Protein-Coupled / Q000276:immunology; D017412:Ribonucleoprotein, U1 Small Nuclear / Q000276:immunology; D012261:Ribonucleoproteins / Q000276:immunology; D012680:Sensitivity and Specificity; D018271:Signal Recognition Particle / Q000276:immunology; D000099207:SS-A Antigen
chemical_list: D000604:Amino Acyl-tRNA Synthetases; D001323:Autoantibodies; D001324:Autoantigens; D005095:Exoribonucleases; D063326:Exosome Multienzyme Ribonuclease Complex; D006643:Histidine-tRNA Ligase; D007155:Immunologic Factors; D056245:Mi-2 Nucleosome Remodeling and Deacetylase Complex; D000090063:Proto-Oncogene Mas; D011518:Proto-Oncogene Proteins; D043562:Receptors, G-Protein-Coupled; D017412:Ribonucleoprotein, U1 Small Nuclear; D012261:Ribonucleoproteins; D018271:Signal Recognition Particle; D000099207:SS-A Antigen; C115323:CHD4 protein, human; C077044:EXOSC10 protein, human